Varian led a round for the targeted cancer drug developer that included fellow existing investors including Johnson & Johnson and Pivotal BioVenture Partners.
Canada-based cancer treatment developer Fusion Pharmaceuticals closed a $105m series B round yesterday led by oncology technology provider Varian Medical Systems that included medical group Johnson & Johnson.
The round also featured Pivotal BioVenture Partners, the healthcare investment firm formed by property developer Nan Fung, as well as OrbiMed, Perceptive Advisors, Rock Springs Capital, HealthCap, Adams Street Partners, TPG Biotech, Seroba Life Sciences, Genesys Capital and Facit.
Johnson and Johnson participated in the round through corporate venturing subsidiary Johnson &…
